EP3589745A1 — A method of modulating the rna methylation
Assigned to Chemestmed Ltd · Expires 2020-01-08 · 6y expired
What this patent protects
Methods and compounds are reported that specifically modulate RNA methylation by activation of the RNA methyltransferase complex METTL3/METTL14. In some embodiments, the compound has binding and/or activation for a METTL3/METTL14/WTAP complex.
USPTO Abstract
Methods and compounds are reported that specifically modulate RNA methylation by activation of the RNA methyltransferase complex METTL3/METTL14. In some embodiments, the compound has binding and/or activation for a METTL3/METTL14/WTAP complex.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.